𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platelet monoamine oxidase B activity in Parkinson's disease: A re-evaluation

✍ Scribed by J. Jarman; V. Glover; M. Sandler; N. Turjanski; G. Stern

Publisher
Springer
Year
1993
Tongue
English
Weight
234 KB
Volume
5
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Association of a monoamine oxidase B all
Association of a monoamine oxidase B allele with Parkinson's disease
✍ Janice H. Kurth; Dr. Matthias C. Kurth; Shirley E. Poduslo; John D. Schwankhaus πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 685 KB

Monoamine oxidase B (MAO-B) is implicated in the cause of Parkinson's disease (PD) because of its role in metabolizing the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine, and forming H,02 during dopamine metabolism. Altered MAO-B activity has been observed in PD platelets. Polymerase chain

A dose-ranging study of selegiline in pa
A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
✍ Nathalie Andreu; Christine Damase-Michel; Jean-Michel Senard; Olivier Rascol; Pr πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 337 KB πŸ‘ 1 views

## Abstract A dose‐ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit β‰₯95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four